Suppr超能文献

整合网络药理学与实验验证解析桂枝茯苓丸治疗子宫腺肌病的机制

Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis.

作者信息

Wang Haoxian, Zhang Jihong, Zhu Qinqin, Fu Xianyun, Li Chenjie

机构信息

The Second People's Hospital of Yichang, YChina Three Gorges University, Yichang 443000, China.

Medical College, China Three Gorges University, Yichang 443002, China.

出版信息

Evid Based Complement Alternat Med. 2021 Oct 26;2021:6034147. doi: 10.1155/2021/6034147. eCollection 2021.

Abstract

AIM

This study aimed to predict the key targets and endocrine mechanisms of Guizhi Fuling Wan (GZFLW) in treating adenomyosis (AM) through network pharmacology, molecular docking, and animal experiment verification.

METHODS

The related ingredients and targets of GZFLW in treating AM were screened out using TCMSP, BATMAN-TCM, SwissTargetPrediction, and PubChem Database. Then, the protein-protein interaction (PPI) analysis and the network of compound-hub targets were constructed. At the same time, the key targets were uploaded to the Metascape Database for KEGG pathway enrichment analysis. After that, the molecular docking technology of the main active components and hub targets was performed. Furthermore, animal experiments were used to verify the results of network pharmacology analysis.

RESULTS

A total of 55 active ingredients of GZFLW and 44 overlapping targets of GZFLW in treating AM were obtained. After screening, 25 hub targets were collected, including ESR1, EGF, and EGFR. Then, the KEGG pathway enrichment analysis results indicated that the endocrine therapeutic mechanism of GZFLW against AM is mainly associated with the estrogen signaling pathway, endocrine resistance, and an EGFR tyrosine kinase signaling pathway. Then, molecular docking showed that the significant compounds of GZFLW had a strong binding ability with ER and EGFR. More importantly, the animal experiments confirmed that the GZFLW could downregulate the abnormal infiltration of the endometrial epithelium into the myometrium and had no interference with the normal sexual cycle. This effect may be directly related to intervening the local estrogen signaling pathway of the endometrial myometrial interface (EMI). It may also be associated with the myometrium cells' estrogen resistance via GPER/EGFR signaling pathway.

CONCLUSION

The endocrine mechanism of GZFLW in treating AM was explored based on network pharmacology, molecular docking, and animal experiments, which provided a theoretical basis for the clinical application of GZFLW.

摘要

目的

本研究旨在通过网络药理学、分子对接和动物实验验证,预测桂枝茯苓丸(GZFLW)治疗子宫腺肌病(AM)的关键靶点和内分泌机制。

方法

利用中药系统药理学数据库与分析平台(TCMSP)、中药系统生物学数据库与分析平台(BATMAN-TCM)、瑞士靶点预测数据库(SwissTargetPrediction)和化学物质数据库(PubChem Database)筛选出GZFLW治疗AM的相关成分和靶点。然后,构建蛋白质-蛋白质相互作用(PPI)分析和化合物-枢纽靶点网络。同时,将关键靶点上传至Metascape数据库进行KEGG通路富集分析。之后,进行主要活性成分与枢纽靶点的分子对接技术研究。此外,采用动物实验验证网络药理学分析结果。

结果

共获得GZFLW的55种活性成分以及GZFLW治疗AM的44个重叠靶点。筛选后,收集到25个枢纽靶点,包括雌激素受体1(ESR1)、表皮生长因子(EGF)和表皮生长因子受体(EGFR)。KEGG通路富集分析结果表明,GZFLW治疗AM的内分泌治疗机制主要与雌激素信号通路、内分泌抵抗以及EGFR酪氨酸激酶信号通路相关。分子对接显示,GZFLW的显著化合物与雌激素受体(ER)和EGFR具有较强的结合能力。更重要的是,动物实验证实GZFLW可下调子宫内膜上皮向肌层的异常浸润,且不干扰正常性周期。这种作用可能直接与干预子宫内膜-肌层界面(EMI)的局部雌激素信号通路有关。也可能与通过G蛋白偶联雌激素受体(GPER)/表皮生长因子受体(EGFR)信号通路产生的肌层细胞雌激素抵抗有关。

结论

基于网络药理学、分子对接和动物实验,探索了GZFLW治疗AM的内分泌机制,为GZFLW的临床应用提供了理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c35/8563128/b05ab02b38ab/ECAM2021-6034147.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验